


Emirates Dermatology Society Fellowship – Summer 2020 Dr Nusayhah Gopee

“I wanted a perfect ending. Now I’ve learned, the hard way, that some poems don’t rhyme, and some stories don’t have a clear beginning, middle, and end. Life is about not knowing, having to change, taking the moment and making the best of it, without knowing what’s going to happen next. Delicious ambiguity.”

– Gilda Radner

The reality of this quote was, yet again, brought home by the coronavirus-related restrictions. I was all prepared and excited to travel to Dubai to present at the Emirates Dermatology Society (EDS) annual conference, looking forward to share experiences with and learn from the different, international speakers, and witness how dermatology is practised in different healthcare settings. However, with newer restrictions and travel bans put in place, my plans had to change.

Instead, I recorded my presentation to be shown at the meeting and attended virtually – a format I am increasingly getting used to! I am very thankful to the EDS organising committee for facilitating this, especially to Sara Hassan, for her support in ensuring this went smoothly and guiding me throughout the process.



The banner features a teal and white color scheme. On the left is a logo for the 2020 Annual Conference with a skyline silhouette. On the right is the circular EDS logo. The central text reads: "Emirates Dermatology Society ANNUAL CONFERENCE 2020 19-21 November 2020 • InterContinental Dubai - Festival City". Below this is the title "Ibrutinib-induced paronychia and periungual granulation – a newly recognised adverse reaction" and the names "Dr NH Gopee" and "Dr B Nasr" with their affiliation "Royal Victoria Infirmary, Newcastle upon Tyne, UK". A small portrait of Dr. Nusayhah Gopee is in the bottom right corner. The website "conference.edsuae.com" is at the bottom center.

I presented two cases of Ibrutinib-induced paronychia and periungual granulation, a newly recognised adverse reaction with only three previous cases reported in the literature. Both patients were receiving Ibrutinib for the treatment of chronic lymphocytic leukaemia and were referred from the haematologists. I discussed the potential pathogenic mechanisms

implicated, the treatment options that could be considered and the importance of early recognition and treatment to prevent debilitating symptoms and preclude the need for stopping Ibrutinib. I was also able to attend an informative session on PLEVA-like rash in Covid-19 by Dr Bassant Abouyamama, a fascinating presentation on facial aesthetics by Dr Islam Kassem and learn some dermoscopy pearls from Dr Maiada Magdy's talk.

Although not exactly the 'perfect ending' I was looking forward to, it was a valuable educational experience as well as an opportunity for reflection on how to adapt to a changing situation and make the best of it. I am grateful to the Emirates Dermatology Society and the British Association of Dermatologists for awarding me this fellowship. I look forward to attending the conference in Dubai in the future, once the 'ambiguity' (not sure I would call it delicious!) due to coronavirus has settled.